{"id":"NCT01151540","sponsor":"Eisai Co., Ltd.","briefTitle":"A Long Term Extension Study of E2080 in Lennox-Gastaut Patients","officialTitle":"A Long Term Extension Study of E2080 in Lennox-Gastaut Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11","primaryCompletion":"2013-08","completion":"2013-08","firstPosted":"2010-06-28","resultsPosted":"2019-03-11","lastUpdate":"2019-03-11"},"enrollment":54,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lennox-Gastaut Syndrome"],"interventions":[{"type":"DRUG","name":"Rufinamide","otherNames":["E2080, BANZEL"]}],"arms":[{"label":"Rufinamide","type":"EXPERIMENTAL"}],"summary":"To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Rufinamide","timeFrame":"From date of first dose up to 30 days after the last dose of study treatment, up to approximately 2 years 10 months","effectByArm":[{"arm":"Rufinamide","deltaMin":54,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":23,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":54},"commonTop":["Nasopharyngitis","Status epilepticus","Somnolence","Vomiting","Contusion"]}}